Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4082 MAD Study in Healthy Overweight/Obese Participants
NCT07388667Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HS-10535 in obesity (5 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience an Adverse Event (AE) at 98 days and Number of Participants Who Discontinue Study Treatment Due to an AE at 84 days. Started Mar 2026; status: completed.
02
Drugs
HS-10535
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07388667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07388667.